by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Neuronal nuclei are normally smoothly surfaced. In Alzheimer’s disease (AD) and other tauopathies, though, they often develop invaginations. We investigated mechanisms and functional consequences of neuronal nuclear invagination in...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE-1 inhibitor umibecestat in cognitively unimpaired 60- to 75-year-old participants at genetic risk for...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION The extent to which the Big Five personality traits and subjective well-being (SWB) are discriminatory predictors of clinical manifestation of dementia versus dementia-related neuropathology is unclear. METHODS Using data from eight independent...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION To examine the burden and clusters of multimorbidity in association with mild cognitive impairment (MCI), dementia, and Alzheimer’s disease (AD)-related plasma biomarkers among older adults. METHODS This population-based study included 5432...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION White matter hyperintensities (WMH) may promote clinical Alzheimer’s disease (AD) disparities between Black American (BA) and non-Hispanic White (nHW) populations. Using a novel measurement, unhealthy white matter connectivity (UWMC), we...
